Uniquity Bio

Uniquity Bio is strategically targeting chronic obstructive pulmonary disease, or #COPD. Beyond COPD, we believe solrikitug, our lead candidate, has potential utility in a wide array of immunology and inflammation programs.    See progress in our pipeline: https://bit.ly/4cSDMZx   #BioPharma #Patients #Innovation

Uniquity Bio is a clinical-stage drug development company built by industry executives with a proven track record. We seek to advance therapeutic programs in #immunology and #inflammation with a laser focus on improving patients’ lives. Meet our seasoned team: https://lnkd.in/g8Y9X_9B #TeamUniquity #Patients #Leadership

Solrikitug, our lead asset, is a human monoclonal antibody, currently in Phase 2 #clinical trials, targeting TSLP that offers broad therapeutic potential in immunology and inflammation. We aim to deliver best-in-class efficacy with solrikitug across several critical respiratory and gastrointestinal indications with significant unmet needs, including #COPD and #asthma.    Learn about solrikitug here: https://bit.ly/3TONe8j     #BioPharma #Science #Healthcare 

At Uniquity Bio, we aim to deliver best-in-class medicines to patients and industry partners while creating value for investors.    Our approach to drug development is built on decades of clinical, development, and regulatory experience and supported by Blackstone Life Sciences. We’re dedicated to the same high standards of scientific rigor and clinical quality upheld by global pharma companies, while our operational agility gives us a competitive edge.     Learn more about how we can work together: https://bit.ly/4eulBeA    #BioPharma #Healthcare #Innovation 

The leadership team at Uniquity Bio encompasses deep experience in immunology and inflammation, we know how to advance an asset through clinical development with an eye toward commercialization.     #TeamUniquity has established a robust manufacturing process to optimize development and advance assets into late-stage trials.    See how we’re making a difference: https://bit.ly/3VR4Xi3    #BioPharma #Innovation 

Uniquity Bio’s sustainable business model supports the parallel development of high-potential medicines along with a range of partnership structures for maximum impact. Starting with our lead asset, a human monoclonal antibody currently in Phase 2 trials, we are poised to build a valuable and dynamic pipeline: https://bit.ly/3TONe8j #BioPharma #Healthcare #Innovation

“This represents a very exciting opportunity to impact a multitude of inflammatory conditions and indications.”      CEO Brian Lortie recently spoke with Ali Gorman of BiotechTV about Uniquity Bio’s unique position in the inflammation and immunology space.    Watch the full interview for #insights into how we're turning our passion for patients into a potential best-in-class asset.     #BioPharma #Healthcare #BiotechNews  

Our #team is dedicated to delivering clinical innovation in immunology and inflammation where there remains significant unmet need.    See how we’re built to lead the industry here: https://bit.ly/3xC3NwN    #Pharma #BioTech #Healthcare 

#ICYMI: Uniquity Bio and CEO Brian Lortie were featured in the Philadelphia Business Journal last week. PBJ covered the launch of our company and the growth of #LifeSciences in the Philadelphia area. Learn more about our mission and approach: https://bit.ly/3QRRxix #BioPharma #Healthcare #Innovation

#NEWS: Uniquity Bio is proud to announce our emergence from stealth with $300 million in committed capital from Blackstone Life Sciences.  In the coming weeks, we will initiate Phase 2 clinical trials of a novel, highly potent TSLP monoclonal antibody, which may have application in chronic obstructive pulmonary disease (COPD) — the third leading cause of death worldwide — and asthma, which is estimated to affect more than 260 million people worldwide.  Read more about how we are well positioned to develop promising therapeutics to patients in need: https://bit.ly/3UPLSuS #COPD #Asthma #BioPharma